Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

This study is currently recruiting participants.
Verified January 2013 by Sarah Cannon Research Institute
Sponsor:
Collaborators:
Onyx Therapeutics, Inc.
Novartis
Information provided by (Responsible Party):
Sarah Cannon Research Institute
ClinicalTrials.gov Identifier:
NCT01496118
First received: December 15, 2011
Last updated: January 31, 2013
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2014
  Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)